Pathogenic Antibodies and (Rapidly Progressive) Dementia syndromes

• Conditions: autoimmune encephalitis; inflamed brain; 10003816; 10007951; 10037173

• Registration Number: NL-OMON47904
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

- Patients aged >= 18 years
- Patients who have given written informed consent
- patients with a clinical profile that fits one the described groups (rapidly progressive dementia of atypical dementia syndromes)

Exclusion Criteria

- Age below 18 years
- Patient objects after initial informed consent
- Patient with mild cognitive impairment (MCI), subjective memory complaints or vascular dementia

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1) The characterization of (new) antibody-related dementia syndromes.<br /><br>2) The frequency of the antibody-mediated dementia syndromes.<br /><br>3) Outcome of autoimmune dementia.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. What clinical and epidemiological markers are linked to the specific,<br /><br>individual antibodies?<br /><br>2. What markers define poor or good prognosis?</p><br>